FY2024 Earnings Estimate for Zoetis Issued By Zacks Research

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Zacks Research raised their FY2024 earnings estimates for shares of Zoetis in a research report issued on Monday, November 25th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $5.89 for the year, up from their previous estimate of $5.81. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q4 2024 earnings at $1.37 EPS, Q1 2025 earnings at $1.45 EPS, Q4 2025 earnings at $1.60 EPS, Q1 2026 earnings at $1.62 EPS and Q3 2026 earnings at $1.77 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.36 EPS.

A number of other analysts also recently issued reports on ZTS. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Down 1.7 %

ZTS stock opened at $175.70 on Wednesday. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a market capitalization of $79.27 billion, a PE ratio of 33.03, a price-to-earnings-growth ratio of 2.74 and a beta of 0.90. The company’s 50-day simple moving average is $184.91 and its 200 day simple moving average is $180.84. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Hedge Funds Weigh In On Zoetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Silvercrest Asset Management Group LLC boosted its holdings in shares of Zoetis by 33.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 12,793 shares of the company’s stock valued at $2,165,000 after acquiring an additional 3,193 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Zoetis during the first quarter valued at about $883,000. B. Riley Wealth Advisors Inc. grew its holdings in shares of Zoetis by 17.4% during the first quarter. B. Riley Wealth Advisors Inc. now owns 16,016 shares of the company’s stock worth $2,786,000 after purchasing an additional 2,370 shares during the last quarter. Tidal Investments LLC raised its holdings in Zoetis by 9.8% in the 1st quarter. Tidal Investments LLC now owns 8,703 shares of the company’s stock valued at $1,471,000 after buying an additional 776 shares during the last quarter. Finally, Hancock Whitney Corp raised its holdings in Zoetis by 7.7% in the 1st quarter. Hancock Whitney Corp now owns 18,531 shares of the company’s stock valued at $3,136,000 after buying an additional 1,319 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.